BACKGROUND: Prior studies indicate that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAID) is associated with a decreased risk of non-small cell lung cancer (NSCLC); however, results have been contradictory in part because of variation in study design. Few studies have examined the use of aspirin or other NSAIDs on risk of NSCLC in women. METHODS: Through a case-control study of African American and Caucasian women with and without NSCLC, we examined the relationship between use of aspirin, NSAIDs, and acetaminophen and risk of NSCLC. Risk was estimated by calculating odds ratios and 95% confidence intervals for ever/never use, duration of use, and duration of use category (never, 1-5 years, >5 years) after adjusting for major risk factors for lung cancer. Risk estimates were stratified by race, age, smoking history, and body mass index. RESULTS: Every use of adult-strength aspirin was associated with a significant reduction in risk of NSCLC (odds ratio, 0.66; 95% confidence interval, 0.46-0.94). Additionally, there was a significant trend toward a reduced risk of NSCLC in adult-strength aspirin users with increasing duration of use (P(trend) = 0.02). In stratified analyses, aspirin use was associated with a significantly reduced risk of lung cancer among Caucasians and 55- to 64-year-olds. Baby aspirin and NSAID use was associated with a significant reduction in risk of NSCLC only among 65- to 74-year-olds. CONCLUSION: Our results suggest that long-term use of adult-strength aspirin may reduce the risk of NSCLC in women.
BACKGROUND: Prior studies indicate that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAID) is associated with a decreased risk of non-small cell lung cancer (NSCLC); however, results have been contradictory in part because of variation in study design. Few studies have examined the use of aspirin or other NSAIDs on risk of NSCLC in women. METHODS: Through a case-control study of African American and Caucasian women with and without NSCLC, we examined the relationship between use of aspirin, NSAIDs, and acetaminophen and risk of NSCLC. Risk was estimated by calculating odds ratios and 95% confidence intervals for ever/never use, duration of use, and duration of use category (never, 1-5 years, >5 years) after adjusting for major risk factors for lung cancer. Risk estimates were stratified by race, age, smoking history, and body mass index. RESULTS: Every use of adult-strength aspirin was associated with a significant reduction in risk of NSCLC (odds ratio, 0.66; 95% confidence interval, 0.46-0.94). Additionally, there was a significant trend toward a reduced risk of NSCLC in adult-strength aspirin users with increasing duration of use (P(trend) = 0.02). In stratified analyses, aspirin use was associated with a significantly reduced risk of lung cancer among Caucasians and 55- to 64-year-olds. Baby aspirin and NSAID use was associated with a significant reduction in risk of NSCLC only among 65- to 74-year-olds. CONCLUSION: Our results suggest that long-term use of adult-strength aspirin may reduce the risk of NSCLC in women.
Authors: Bela Kis; James A Snipes; Steve A Simandle; David W Busija Journal: Am J Physiol Regul Integr Comp Physiol Date: 2004-12-23 Impact factor: 3.619
Authors: Nancy R Cook; I-Min Lee; J Michael Gaziano; David Gordon; Paul M Ridker; JoAnn E Manson; Charles H Hennekens; Julie E Buring Journal: JAMA Date: 2005-07-06 Impact factor: 56.272
Authors: H Achiwa; Y Yatabe; T Hida; T Kuroishi; K Kozaki; S Nakamura; M Ogawa; T Sugiura; T Mitsudomi; T Takahashi Journal: Clin Cancer Res Date: 1999-05 Impact factor: 12.531
Authors: Valerie A McCormack; Rayjean J Hung; Darren R Brenner; Heike Bickeböller; Albert Rosenberger; Joshua E Muscat; Philip Lazarus; Anne Tjønneland; Søren Friis; David C Christiani; Eun-Mi Chun; Loic Le Marchand; Gad Rennert; Hedy S Rennert; Angeline S Andrew; Irene Orlow; Bernard Park; Paolo Boffetta; Eric J Duell Journal: Cancer Causes Control Date: 2011-10-11 Impact factor: 2.506
Authors: Patricia Erickson; Lisa D Gardner; Christopher A Loffredo; Diane Marie St George; Elise D Bowman; Janaki Deepak; Khadijah Mitchell; Claire L Meaney; Patricia Langenberg; Debra H Bernat; Sania Amr; Bríd M Ryan Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-08-31 Impact factor: 4.254
Authors: Christopher G Slatore; David H Au; Alyson J Littman; Jessie A Satia; Emily White Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-17 Impact factor: 4.254
Authors: Laura M Beaver; Erik J Stemmy; Stephanie L Constant; Arnold Schwartz; Laura G Little; Jason P Gigley; Gina Chun; Kent D Sugden; Susan M Ceryak; Steven R Patierno Journal: Toxicol Appl Pharmacol Date: 2008-12-09 Impact factor: 4.219
Authors: Carol J Etzel; Sumesh Kachroo; Mei Liu; Anthony D'Amelio; Qiong Dong; Michele L Cote; Angela S Wenzlaff; Waun Ki Hong; Anthony J Greisinger; Ann G Schwartz; Margaret R Spitz Journal: Cancer Prev Res (Phila) Date: 2008-09
Authors: Laura M Beaver; Erik J Stemmy; Arnold M Schwartz; Jesse M Damsker; Stephanie L Constant; Susan M Ceryak; Steven R Patierno Journal: Environ Health Perspect Date: 2009-08-19 Impact factor: 9.031